Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Fluticasone furoate; Drug: Placebo; Drug: Montelukast; Drug: Short Acting Beta 2 Agonist
Sponsor: GlaxoSmithKline
Not yet recruiting – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: MK-0887A 100/10 mcg; Drug: MK-0887 100 mcg; Drug: Albuterol/Salbutamol; Drug: Prednisone/Prednisolone
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting – verified April 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: QMF149; Drug: QMF149; Drug: MF 400; Drug: MF 400; Drug: salmeterol /fluticasone
Sponsor: Novartis Pharmaceuticals
Not yet recruiting – verified September 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Fluticasone Furoate (Asthma) – Forecast and Market Analysis to 2023: Research …
Medgadget.com (blog) The Report Fluticasone Furoate (Asthma) – Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz. GlobalData has released … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Fluticasone furoate; Drug: Placebo; Drug: Salbutamol
Sponsor: GlaxoSmithKline
Not yet recruiting – verified July 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: FF; Drug: Placebo; Drug: Montelukast; Drug: Albuterol/Salbutamol
Sponsor: GlaxoSmithKline
Not yet recruiting – verified June 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Rhinitis, Allergic, Perennial and Seasonal
Interventions: Drug: FF nasal spray; Drug: MF nasal spray
Sponsor: GlaxoSmithKline
Not yet recruiting – verified March 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the …
MarketWatch 20, 2014 /PRNewswire/ — GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic … |
View full post on asthma – Google News
|
Once-Daily Fluticasone Furoate May Be Effective for Persistent Asthma
Monthly Prescribing Reference A new study published in the journal Respiratory Research evaluates the use of a once-daily dosing regimen for the inhaled corticosteroid (ICS) fluticasone furoate vs. placebo in patients with asthma uncontrolled by non-inhaled corticosteroids … |
View full post on asthma – Google News
|
Fluticasone furoate effective in moderate-to-severe asthma
News-Medical.net Once daily fluticasone furoate, used at a dose of 100 µg or 200 µg, provides substantial improvements in lung function and asthma control for patients with uncontrolled moderate-to-severe asthma, phase III trial results show. “Numerically greater … |
View full post on asthma – Google News